The Lung Cancer Disease Site Group (Lung Cancer DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. Reports produced by this group are available below.

Lung Cancer DSG Publications

The following document was developed by patient representatives to help patients and their families and friends understand lung cancer:

• Understanding Lung Cancer

Non-Small Cell Lung Cancer

• Postoperative Adjuvant Radiation Therapy in Stage II or IIIA Completely Resected Non-Small Cell Lung Cancer
  7-1-1 PG: February 2005 Update
  
  • Summary
  • Summary & Full Report
• Postoperative Adjuvant Chemotherapy, with or without Radiotherapy, in Completely Resected Non-Small Cell Lung Cancer
  7-1-2 EBS: December 2006 Update


• Practice Guideline
• Evidence-Based Series

Systematic Review : “Reprinted from The Annals of Thoracic Surgery, Vol 81, Alam N, Darling G, Shepherd FA, Mackay JA, Evans WK, and the Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care, Postoperative chemotherapy in non-small cell lung cancer: a systematic review, Pages No. 1926-36, Copyright 2006, with permission from the Society of Thoracic Surgeons. All rights reserved.”

• Postoperative Adjuvant Chemotherapy in Completely Resected Non-Small Cell Lung Cancer: Guidance for Nurses

NPG: December 2007

• Guidance
• Chemotherapy in Stage IV (Metastatic) Non-Small Cell Lung Cancer
  

  November 2009 : This document has been retired and has been being incorporated into PG#7-10: the role of first-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer.

• Management of Unresected Stage III Non-Small Cell Lung Cancer
  7-3 EBS Version 2.2005: January 2006 Update
  
  • Practice Guideline
  • Evidence-Based Series
• Use of Preoperative Chemotherapy with or without Postoperative Radiotherapy in Technically Resectable Stage IIIA Non-Small Cell Lung Cancer

  7-4 PG: April 2002 Update

  • Summary
  • Summary & Full Report


• Use of Vinorelbine in Non-Small Cell Lung Cancer
  

  November 2009 : This document has been retired and has been incorporated into PG#7-10: The role of first-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer.

• The Role of Taxanes in First-line Therapy for Advanced Non-Small Cell Lung Cancer

  November 2009 : This document has been retired and has been incorporated into PG#7-10: The role of first-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer.

• The Role of Single-Agent Docetaxel (Taxotere®) as a Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer
  7-7-2 PG

  March 2006 : This document has been retired and incorporated in EBS 7-19: Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer.

• Use of Gemcitabine in Non-Small Cell Lung Cancer
  

  November 2009 : This document has been retired and has been incorporated into PG#7-10: The role of first-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer.

• Use of the Epidermal Growth Factor Receptor Inhibitors, Gefitinib (Iressa) and Erlotinib (Tarceva), in the Treatment of Non-small Cell Lung Cancer
  7-9 EBS: January 2006 Update
  
  • Practice Guideline
  • Evidence-Based Series
• First Line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
  7-10 EBS: September 2009 Update
  
  • Practice Guideline
  • Evidence-Based Series
• Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer
  7-12 PG: September 2002 Update
  
  • Summary
  • Summary & Full Report
• The Role of Photodynamic Therapy (PDT) in Patients with Non-Small Cell Lung Cancer
  7-15 EBS: November 2005 Update
  
  • Practice Guideline
  • Evidence-Based Series
• The Role of High Dose Rate Brachytherapy in the Palliation of Patients with Non-small Cell Lung Cancer
  7-16 EBS: October 2005
  
  • Practice Guideline
  • Evidence-Based Series
• Second line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer
  7-19 EBS: March 2006
  
  • Practice Guideline
  • Evidence-Based Series

The following EBS reports are in development and only their titles are available at this time:
Radical Radiotherapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer (7-21 EBS)

Small Cell Lung Cancer

• The Role of Combination Chemotherapy in the Initial Management of Limited-Stage Small-Cell Lung Cancer
  7-13-1 PG: December 2003 Update
  
  • Summary
  • Summary & Full Report
• Prophylactic Cranial Irradiation in Small Cell Lung Cancer
  7-13-2 PG: November 2003 Update
  
  • Summary
  • Summary & Full Report
• The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer
  7-13-3 PG: January 2003 Update
  
  • Summary
  • Summary & Full Report
• Chemotherapy for Relapsed Small Cell Lung Cancer
  7-17 EBS: August 2006
  
  • Practice Guideline
  • Evidence-Based Series

Non-Small Cell and Small Cell Lung Cancer

• 18-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer
  7-20 EBS: April 2007
  
  • Practice Guideline
  • Evidence-Based Series

Mesothelioma

• The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma
  7-14-1 EBS: October 2005 Update
  
  • Practice Guideline
  • Evidence-Based Series
• Surgical Management of Malignant Pleural Mesothelioma
  7-14-2 EBS: August 2005
  
  • Practice Guideline
  • Evidence-Based Series
• The Role of Radiation Therapy in Malignant Pleural Mesothelioma
  7-14-3 EBS: February 2006
  
  • Practice Guideline
  • Evidence-Based Series

Thymoma

• The Management of Thymoma
  7-11 EBS: September 2008
  
  • Practice Guideline
  • Evidence-Based Series